No Detail Found!

Efficacy of Combination Therapy Sofosbuvir Plus Velpatasvir in Treatment of Hepatitis C Virus(HCV)

Author(s)
Shahzad Latif Department of Gastroenterology, Akhtar Saeed Medical and Dental College, Lahore, Pakistan
Wafa Qaisar Department of Medicine, Rashid Latif Medical and Dental College, Lahore, Pakistan
Hafiza Qaria Bushra Saleem Nawaz Sharif Social Security Hospital, Multan road, Lahore, Pakistan
Tariq Waseem Department of Medicine, Akhtar Saeed Medical and Dental Ccollege, Lahore, Pakistan
Zartasha Hanan Khan Department of Community Medicine, Akhtar Saeed Medical and Dental College, Lahore, Pakistan
Abstract
Objective: To assess the treatment response and tolerance in HCV patients without doing genotypes. Method: An interventional study was conducted to evaluate the efficacy and sustained virologic response (SVR) of 200 patients suffering with hepatitis C after an intervention of once-daily Sofosbuvir 400 mg plus Velpatasvir 100 mg for 12 weeks at Akhtar Saeed Trust hospital and Farooq Hospital Lahore between December 2019 to December 2021.The sample size was calculated by using keeping margin of error at 5%, confidence level at 95%, population size 20000 and response rate at 30%. Patients were followed up on weekly basis with CBC, LFTS and RFTS and HCV RNA by PCR at 4th week and six months after completion of 12 weeks treatment. With SPSS 23, Chi square test was applied and p-value of < 0.05 was considered significant. Results: In this interventional study out of 200 hepatitis C positive patients 139(63.5%) were males and 61(27.9%) were females. A significant association was observed between gender (p=0.000), presenting complaints (p =0.002) abdominal ultrasound findings (0.004), status of patient (p=0.015), comorbidities (p= 0.042) and lab investigations (p=0.000). Various side effects were reported by 69(31.5%) experienced headaches, 60(27.4%) experienced dyspepsia, 57(26%) experienced nausea as a result of this combination therapy. Conclusion: Twelve weeks of treatment with combination therapy of sofosbuvir and Velpstasvir is well tolerated and has high SVR in HCV patients with all types of genotypes.
Publication Details
Page(s) 390-394
Published Journal: ESCULAPIO. JOURNAL OF SERVICES INSTITUTE OF MEDICAL SCIENCES, Volume: 18, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Efficacy, Hepatitis C, Combination therapy
0

Citations

0

Downloads

74

Views